Severe Lactic Acidosis in Association with Reverse Transcriptase Inhibitors with Potential Response to L-Carnitine in a Pediatric HIV-Positive Patient

AIDS Patient Care and STDs

Volumn 18, Issue 3, 2004, Pages 131-134

  Carter, Robert W ^a   Singh, Jasjit ^b   Archambault, Christian ^c   Arrieta, Antonio ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c Paradise Valley Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; DICHLOROACETIC ACID; DIDANOSINE; GABAPENTIN; LACTIC ACID; LAMIVUDINE; LORATADINE; MEGESTROL; NEVIRAPINE; RIBOFLAVIN; RISPERIDONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIAMINE; TOPIRAMATE; TUMS; UBIQUINONE; ZIDOVUDINE;

ABDOMINAL PAIN; ARTICLE; CASE REPORT; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; FATTY LIVER; HEMOFILTRATION; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LETHARGY; LYMPHOCYTE COUNT; MALE; METABOLIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MYOPATHY; NAUSEA; OXIDATIVE PHOSPHORYLATION; PANCREATITIS; SCHOOL CHILD; TACHYPNEA; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION; VIRUS LOAD; VOMITING;

ACIDOSIS, LACTIC; CARNITINE; CHILD; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 1842510443     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104322994810     Document Type: Article

References (22)

1. Shaer AJ, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. Am J Nephrol 2000;20:332-338.
2. Khoukri S, Cashing H. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy. AIDS Read 2000;10:602-606.
3. Ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-616.
4. Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol 2001;12(Suppl 7):S15-19.
5. Shikuma CM, Shiramizu B. Mitochondrial toxicity associated with nucleoside reverse transcriptase inhibitor therapy. Curr Infect Dis Rep 2001;3:553-560.
6. Claessens Y, Cariou A, Chiche J, Dauriat G, Dhainaut J. L-Carnitine as a treatment of life-threatening lactic acidosis induce by nucleoside analogues. AIDS 2000; 14:472-473.
7. Dalton SD, Rahimi AR. Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis. AIDS Patient Care STD 2001;15:611-614.
8. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:714-723.
9. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937.
10. Boffito M, Marietti G, Audagnotto S, et al. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2002;155:558-559.
11. Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with HIV: A report of 12 cases. Clin Infect Dis 2001;33:1914-1921.
12. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-166.
13. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-2730.
14. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with NRTIs: A case-control study. Clin Infect Dis 2003;36:1324-1328.
15. Hocqueloux L, Alberti C, Feugeas JP, et al. Prevalence, risk factors and outcome of hyperlactatemia in HIV-infected patients. HIV Med 2003;4:18-23.
16. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000;57:190-193.
17. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
18. Posteraro AF III, Mauriello M, Winter SM. Riboflavin treatment of antiretroviral induced lactic acidosis and hepatic steatosis. Conn Med 2001;65:387-90.
19. Parillo JE, Bone RC, eds. Critical Care Medicine: Principles of Diagnosis and Management. St. Louis, MO; Mosby, 1995:1380.
20. Lonergan JT, et al. 7th CROL, San Francisco, CA 2000. Abstract 56.
21. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 25003;22:778-782.
22. Alimenti A, Burdge D, Ogilvie G, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22:782-788.